|Day Low/High||86.50 / 91.11|
|52 Wk Low/High||62.48 / 110.36|
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer reacts to the Syria missile strikes and the weaker-than-expected March jobs report.
"I would say that (today) the averages are faring better than the average stock -- on average. If you know what I mean!" -- Kass Diary, Consider this Yogiism! With opening day yesterday and tonite's NCAA final (I like North Carolina in a high sin...
It's pretty normal to have profit-taking after such a strong first quarter.
Home builders make up the second-largest allocation in my portfolio, behind biotech.
Approach the long side of this great biopharma play on any shallow dip in price, like one or two dollars.
There are nearly too many surging sectors to count.
These four biotech stocks have been moving on some interesting news and clinical results.
A trade at $126 will be a new high for the move up.
Animal health and oncology deal activity is heating up in 2017.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
With the election resolved, biotech could be ripe for consolidation.
Prices have marched their way all the way back up to the bottom end of key resistance.
Investors should try and profit from the market’s volatility, not run away from it, said Jim Jubak, author of Juggling With Knives.
These biotech/pharma picks could give you a very happy new year.
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
These three stocks have re-established the importance of a prior technical level and are in position to move higher off this support.